Yield10 Bioscience, INC

Yield10 Bioscience and its subsidiaries have filed for Chapter 11 bankruptcy and intend to sell substantially all of their assets.

Yield10 Bioscience's proposed asset sale to Nuseed and subsequent dissolution were not approved by shareholders at the adjourned special meeting.

Yield10 Bioscience's special meeting to approve the sale of assets to Nuseed and company dissolution was adjourned due to a lack of sufficient shareholder votes, with a reconvened meeting scheduled for November 21, 2024.

Yield10 Bioscience reports the resignation of Dr. Kristi D. Snell as Vice President Research and Chief Science Officer, effective October 29, 2024.

Yield10 Bioscience has entered into an agreement to sell substantially all of its assets to Nuseed Nutritional US Inc. for up to $5 million, and plans to liquidate the company following the sale.

Yield10 Bioscience has obtained a secured promissory note of up to $3 million from Nuseed Nutritional US Inc., with an initial draw of $500,000, while continuing negotiations for a potential asset sale to Nuseed.

Yield10 Bioscience announced its Q2 2024 financial results and is focusing on a potential asset sale to Nufarm, while managing its limited cash resources.

Yield10 Bioscience reported its Q1 2024 financial results, highlighting a focus on commercializing sustainable Camelina products while navigating financial constraints and Nasdaq delisting.

Yield10 Bioscience shifts its biofuel strategy to focus on R&D services and licensing, while advancing its omega-3 Camelina program towards commercialization.

Kristi Snell, VP of Research and CSO at Yield10 Bioscience, reports a transaction involving common stock related to tax withholding upon RSU vesting.

Lynne H. Brum, VP of Planning and Communications at Yield10 Bioscience, reports the withholding of shares for tax obligations and acquisition of shares through the company's 401(k) plan.

Charles B. Haaser, VP Finance and CAO of Yield10 Bioscience, reports the withholding of shares for tax obligations and acquisition of shares through the company's 401(k) plan.

Oliver P. Peoples, CEO of Yield10 Bioscience, reports changes in beneficial ownership of company stock due to tax withholding and 401(k) contributions.

Director Jack W. Schuler reported the sale of 36,000 shares of Yield10 Bioscience, Inc. common stock at $0.20 per share on December 20, 2023.

Director Robert L. Van Nostrand acquired 11,924 shares of Yield10 Bioscience in lieu of cash compensation for board service during Q1 2024.

Yield10 Bioscience is set to sell substantially all of its assets to Nuseed Nutritional US Inc. and subsequently liquidate and dissolve the company, pending stockholder approval.

Yield10 Bioscience is holding its 2024 annual meeting to vote on key proposals including increasing authorized shares, approving warrant issuance, and executive compensation.

Yield10 Bioscience is asking stockholders to approve a reverse stock split to increase its share price and maintain its Nasdaq listing.

Yield10 Bioscience is filing an amendment to its S-1 registration statement to include adjusted financial data reflecting a reverse stock split and updates regarding its common stock trading on the OTC market, related to the potential resale of shares issuable upon the exercise of outstanding warrants.

Yield10 Bioscience is filing an amendment to its S-1 registration statement to allow selling security holders to resell shares of common stock issuable upon exercise of outstanding warrants.

Yield10 Bioscience is seeking to raise capital through an offering of units consisting of common stock or pre-funded warrants and common warrants.

Yield10 Bioscience is registering for the resale of up to 6,382,280 shares of its common stock, issuable upon the exercise of outstanding warrants held by selling security holders.